Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Neutrophil‐to‐lymphocyte ratio is associated with survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib
Toshifumi Tada, Takashi Kumada, Atsushi Hiraoka, et al.
Liver International (2020) Vol. 40, Iss. 4, pp. 968-976
Closed Access | Times Cited: 73

Showing 1-25 of 73 citing articles:

Usefulness of neutrophil-to-lymphocyte ratio (NLR) as a prognostic predictor after treatment of hepatocellular carcinoma." Review article
Mohamad Mouchli, Shravani Reddy, Miranda Gerrard, et al.
Annals of Hepatology (2020) Vol. 22, pp. 100249-100249
Open Access | Times Cited: 92
Clinical Significance of Adverse Events for Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective Study
Shigeo Shimose, Hideki Iwamoto, Takashi Niizeki, et al.
Cancers (2020) Vol. 12, Iss. 7, pp. 1867-1867
Open Access | Times Cited: 71
The importance of liver functional reserve in the non-surgical treatment of hepatocellular carcinoma
Delia D’Avola, Alessandro Granito, Manuel de la Torre‐Aláez, et al.
Journal of Hepatology (2021) Vol. 76, Iss. 5, pp. 1185-1198
Open Access | Times Cited: 66
Neutrophil–lymphocyte ratio predicts early outcomes in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: a multicenter analysis
Toshifumi Tada, Takashi Kumada, Atsushi Hiraoka, et al.
European Journal of Gastroenterology & Hepatology (2022) Vol. 34, Iss. 6, pp. 698-706
Closed Access | Times Cited: 48
Efficacy and Safety of TACE Combined With Lenvatinib Plus PD-1 Inhibitors Compared With TACE Alone for Unresectable Hepatocellular Carcinoma Patients: A Prospective Cohort Study
Shuping Qu, Xiaobing Zhang, Yutian Wu, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 39
Blood biomarkers predict outcomes in patients with hepatocellular carcinoma treated with immune checkpoint Inhibitors: A pooled analysis of 44 retrospective sudies
Lilong Zhang, Jiarui Feng, Tianrui Kuang, et al.
International Immunopharmacology (2023) Vol. 118, pp. 110019-110019
Open Access | Times Cited: 35
Geriatric nutritional risk index and newly developed scoring system as prognosis prediction for unresectable hepatocellular carcinoma patients treated with lenvatinib
Hideko Ohama, Atsushi Hiraoka, Toshifumi Tada, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access | Times Cited: 1
Immune Checkpoint Inhibitor in Hepatocellular Carcinoma: Response Rates, Adverse Events, and Predictors of Response
Shekhar Swaroop, Sagnik Biswas, Shubham Mehta, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 3, pp. 1034-1034
Open Access | Times Cited: 1
Lenvatinib prolongs the progression‑free survival time of patients with intermediate‑stage hepatocellular carcinoma refractory to transarterial chemoembolization: A multicenter cohort study using data mining analysis
Shigeo Shimose, Takumi Kawaguchi, Masatoshi Tanaka, et al.
Oncology Letters (2020) Vol. 20, Iss. 3, pp. 2257-2265
Open Access | Times Cited: 54
Lenvatinib for Hepatocellular Carcinoma: A Literature Review
Takeshi Hatanaka, Atsushi Naganuma, Satoru Kakizaki
Pharmaceuticals (2021) Vol. 14, Iss. 1, pp. 36-36
Open Access | Times Cited: 53
The Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab
Jing‐Houng Wang, Yen‐Yang Chen, Kwong‐Ming Kee, et al.
Cancers (2022) Vol. 14, Iss. 2, pp. 343-343
Open Access | Times Cited: 35
Usefulness of neutrophil‐to‐lymphocyte ratio in predicting progression and survival outcomes after atezolizumab–bevacizumab treatment for hepatocellular carcinoma
Hironori Ochi, Masayuki Kurosaki, Kouji Joko, et al.
Hepatology Research (2022) Vol. 53, Iss. 1, pp. 61-71
Open Access | Times Cited: 34
Real Life Study of Lenvatinib Therapy for Hepatocellular Carcinoma: RELEVANT Study
Andrea Casadei‐Gardini, Margherita Rimini, Masatoshi Kudo, et al.
Liver Cancer (2022) Vol. 11, Iss. 6, pp. 527-539
Open Access | Times Cited: 30
Machine Learning to Predict the Response to Lenvatinib Combined with Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma
Jun Ma, Zhiyuan Bo, Zhengxiao Zhao, et al.
Cancers (2023) Vol. 15, Iss. 3, pp. 625-625
Open Access | Times Cited: 18
Neutrophils: Driving inflammation during the development of hepatocellular carcinoma
Hong Chen, Xing-Hao Zhou, Jingru Li, et al.
Cancer Letters (2021) Vol. 522, pp. 22-31
Closed Access | Times Cited: 37
Safety and efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma in early clinical practice: A multicenter analysis
Makoto Chuma, Haruki Uojima, Nobuhiro Hattori, et al.
Hepatology Research (2021) Vol. 52, Iss. 3, pp. 269-280
Closed Access | Times Cited: 37
Kinetics of the neutrophil‐lymphocyte ratio during PD‐1 inhibition as a prognostic factor in advanced hepatocellular carcinoma
Won‐Mook Choi, Ji Yoon Kim, Jonggi Choi, et al.
Liver International (2021) Vol. 41, Iss. 9, pp. 2189-2199
Closed Access | Times Cited: 35
Inflammation and Myeloid Cells in Cancer Progression and Metastasis
Jenying Deng, Jason B. Fleming
Frontiers in Cell and Developmental Biology (2022) Vol. 9
Open Access | Times Cited: 28
Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma
Xuyang Song, Robin Kate Kelley, Anis A. Khan, et al.
Clinical Cancer Research (2022) Vol. 29, Iss. 4, pp. 754-763
Open Access | Times Cited: 24
Platelet‐to‐lymphocyte ratio a potential prognosticator in acute myocardial infarction: A prospective longitudinal study
Hongling Wang, Li Li, Yi Ma
Clinical Cardiology (2023) Vol. 46, Iss. 6, pp. 632-638
Open Access | Times Cited: 16
The neutrophil‐to‐lymphocyte ratio at the start of the second course during atezolizumab plus bevacizumab therapy predicts therapeutic efficacy in patients with advanced hepatocellular carcinoma: A multicenter analysis
Sho Matoya, Takanori Suzuki, Kentaro Matsuura, et al.
Hepatology Research (2023) Vol. 53, Iss. 6, pp. 511-521
Closed Access | Times Cited: 13
Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives
Yuhang Chen, Shengyuan Dai, Chien‐shan Cheng, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 5
Comparison of the prognostic effect of sarcopenia on atezolizumab plus bevacizumab and lenvatinib therapy in hepatocellular carcinoma patients
Katsuya Toshida, Shinji Itoh, Takahiro Tomiyama, et al.
JGH Open (2022) Vol. 6, Iss. 7, pp. 477-486
Open Access | Times Cited: 20
Prognostic significance of sarcopenia in patients with hepatocellular carcinoma treated with lenvatinib
Dong Dong, Jinyu Shi, Xiao Shang, et al.
Medicine (2022) Vol. 101, Iss. 5, pp. e28680-e28680
Open Access | Times Cited: 19
Neoadjuvant therapy: Dawn of reducing the high post-surgery recurrence rate of hepatocellular carcinoma
Xiaodong Zhang, Luyi Zhang, Jialiang Luo, et al.
World Journal of Gastrointestinal Surgery (2025) Vol. 17, Iss. 3
Closed Access
Page 1 - Next Page

Scroll to top